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Background: Non-invasive measurements of 24 hour ambulatory central aortic systolic pressure (24 h-CASP) and
central pulse pressure (24 h-CPP) are now feasible. We evaluate the relationship between 24 h central blood
pressure and diabetes-related complications in patients with type 1 diabetes.
Methods: The study was cross-sectional, including 715 subjects: 86 controls (C), 69 patients with short diabetes
duration (< 10 years), normoalbuminuria (< 30 mg/24 h) without receiving antihypertensive treatment (SN), 211
with longstanding diabetes (≥ 10 years) and normoalbuminuria (LN), 163 with microalbuminuria (30-299 mg/24 h)
(Mi) and 186 with macroalbuminuria (> 300 mg/24 h) (Ma).
24 h-CASP and 24 h-CPP was measured using a tonometric wrist-watch-like device (BPro, HealthStats, Singapore)
and derived using N-point moving average.
Results: In C, SN, LN, Mi and Ma mean ± SD 24 h-CASP was: 114 ± 17, 115 ± 13, 121 ± 13, 119 ± 16 and 121 ±
13 mmHg (p < 0.001); and 24 h-CPP: 38 ± 8, 38 ± 7, 44 ± 10, 46 ± 11 and 46 ± 11 mmHg, (p < 0.001).
Following rigorous adjustment (24 h mean arterial pressure and conventional risk factors), 24 h-CASP and 24 h-CPP
increased with diabetes, albuminuria degree, previous cardiovascular disease (CVD), retinopathy and autonomic
dysfunction (p ≤ 0.031).
Odds ratios per 1 standard deviation increase in 24 h-CASP, 24 h-CPP and 24 h systolic blood pressure (24 h-SBP)
were for CVD: 3.19 (1.68-6.05), 1.43 (1.01-2.02) and 2.39 (1.32-4.33), retinopathy: 4.41 (2.03-9.57), 1.77 (1.17-2.68) and
3.72 (1.85-7.47) and autonomic dysfunction: 3.25 (1.65-6.41), 1.64 (1.12-2.39) and 2.89 (1.54-5.42).
Conclusions: 24 h-CASP and 24 h-CPP was higher in patients vs. controls and increased with diabetic
complications independently of covariates. Furthermore, 24 h-CASP was stronger associated to complications than
24 h-SBP.
The prognostic significance of 24 h-CASP and 24 h-CPP needs to be determined in follow-up studies.
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Blood pressure (BP) control is of paramount importance
in prevention of complications in type 1 diabetes [1-3].
Despite improved medical therapy over recent decades,
complications still impact many diabetic patients dimini-
shing quality of life and contributing to premature mortal-
ity. Moreover, monitoring and managing complications in
patients with type 1 diabetes confers significant healthcare
expenditure [4], and improved screening, monitoring and
prevention strategies are warranted.
Routinely, seated BP measurements are recorded over
the brachial artery in the physician’s office. However, in-
creasing evidence points towards superior predictive value
of out-of-office measurements such as 24 hour ambulatory
BP (AMBP) [5] and home BP monitoring [6]. Recent stud-
ies indicate additional benefit from non-invasive assess-
ment of central aortic systolic pressure (CASP) and
central pulse pressure (CPP) as compared to routine
measurement of brachial pressure [7-9].
Central and brachial pressures are mutually influenced
by cardiac output, vascular resistance and conduit artery
rigidity. Whilst mean arterial pressure (MAP) is relatively
constant across large arteries, systolic pressure waves are
amplified as they move from the aortic root to the brachial
artery. This amplification results in a higher brachial sys-
tolic BP (SBP) relative to the corresponding CASP [10].
With aging [11] and/or diabetes [12] alterations in large
artery composition associated with increased arterial stiff-
ness, augmented blood flow and increased pressure wave
reflections, impact more on CASP relative to SBP. In
addition, antihypertensive treatment (AHT) may alter the
relationship between CASP and SBP, resulting in different
effects on CASP relative to SBP [13,14]. This might under-
pin different outcome benefits between classes of AHT
drugs despite targeting to similar levels of SBP [15].
Measurement of ambulatory 24 h-CASP and 24 h-CPP
are now feasible, and a recent study showed a difference
in central and brachial diurnal patterns, which could imply
that central BP possess additional prognostic value [16].
We investigate the associations between 24 h-CASP and
24 h-CPP, and impaired kidney function, history of cardio-
vascular disease (CVD), left ventricular hypertrophy
(LVH), retinopathy, and autonomic dysfunction in patients
with type 1 diabetes.
Methods
Study population
Between September 2009 and June 2011, Caucasian pa-
tients with TIDM, were recruited to enter a cross-sectional
study at Steno Diabetes Center, Copenhagen, Denmark.
Recruitment was in sequential order according to date of
birth from a list of all patients attending the outpatient
clinic. For power calculations we used an α-value of 5%, a
β-value of 20%, and an estimated variance of 9.5 mmHg.For the comparison between controls and patients we esti-
mated a 24 h-CASP-difference of 4 mmHg between
groups, which implied that we needed a minimum of 45
participants in each group. For the comparisons between
patient groups (3 albuminuria groups), we estimated a
24 h-CASP-difference of 2 mmHg, indicating a need for
177 patients in each group. Thus, we intended to include
at least 45 controls and 576 patients. Of 1285 patients in-
vited, 676 (52.6%) agreed to enter the study. Patients de-
clining participation were younger but with similar gender
distribution compared to participating patients (49 ±
16 years and 57% males vs. 54 ± 13 years and 56% males
(p < 0.001 and 0.62). In addition, a control group of 51
non-diabetic subjects from Copenhagen, Denmark and 46
non-diabetic subjects from Leichester, UK were included.
In total, 654 (96.7%) patients and 90 (92.9%) controls
had adequate ambulatory AMBP available, with 46 ± 7
and 18 ± 3 (63.9% and 75.0% of total possible) recordings
during day and night, respectively. Four controls and 25
patients with normoalbuminuria and short diabetes dur-
ation received AHT and were excluded in order to create
two comparable groups not treated for hypertension. The
remaining groups of patients had no restriction regarding
AHT (Table 1). Hence, the analysed cohort included 715
subjects, comprising of 86 non-diabetic persons (C), 69
patients with short diabetes duration (< 10 years),
normoalbuminuria (< 30 mg/24 h) and not receiving AHT
(SN), 211 patients with longstanding diabetes (≥ 10 years)
and normoalbuminuria (LN), 163 patients with
microalbuminuria (30-299 mg/24 h) (Mi), and 186 pa-
tients with macroalbuminuria (> 300 mg/24 h) (Ma).
Figure 1 summarise the inclusion and exclusion of the
study participants. The 10 year cut-off for defining patients
as having short vs. long duration of diabetes was chosen, as
complications to diabetes may develop within 5–10 years
[17]. The five groups were stratified in order to create
groups for comparison of 1) healthy controls to patients
without complications, 2) healthy controls to patients with
sustained normal kidney function, and 3) patients with
increasing degree of impaired kidney function.
Patients with ESRD, defined as receiving dialysis or renal
transplantation, or GFR/eGFR < 15 ml/min/1.73 m2 were
not included.
The study conformed to the Declaration of Helsinki,
was approved by the Danish National Committee on
Biomedical Research Ethics (2009–056), and all partici-
pants gave written informed consent.
Clinical and laboratory methods
Participant attended one single study visit, during which
all clinical and laboratory measurements were performed.
For office BP, 15 minutes supine rest was followed by re-
cording and averaging of three separate left brachial mea-
surements (A&D Medical, UA787).







normo- vs. micro- vs.
macroalbuminuria
Short duration Long duration Micro Macro
p p
n = 629 n = 86 n = 69 n = 211 n = 163 n = 186
Female (%) 44 44 39 53 38 42 0.84 0.010
Age (years) 54 ± 13 49 ± 12 39 ± 13 57 ± 11 58 ± 13 55 ± 10 <0.001 0.031
Diabetes duration (years) 34 ± 15 n/a 6 ± 3 38 ± 11 35 ± 15 38 ± 11 N/A 0.056
HbA1c (mmol/mol) 64 ± 13 35 ± 3 65 ± 13 62 ± 10 65 ± 13 68 ± 14 <0.001 <0.001
Total cholesterol (mmol/l) 4.7 ± 0.9 5.5 ± 0.9 4.7 ± 0.8 4.8 ± 0.7 4.6 ± 0.8 4.6 ± 1.0 <0.001 0.23
Body mass index (kg/m2) 25.5 ± 5.9 26.6 ± 5.2 24.2 ± 3.2 25.0 ± 3.8 25.8 ± 4.1 26.3 ± 9.1 0.001 0.045
eGFR (ml/min/1.73 m2) 83 ± 28 96 ± 16 107 ± 21 90 ± 20 85 ± 26 62 ± 29 <0.001 <0.001
*UAER (mg/24-h) 18 (2–8271) 14 (4–157) 10 (4–39) 7 (2–236) 33 (4–4512) 130 (4–8271) 0.36 <0.001
Smokers (%) 21 6 23 18 19 25 0.002 0.18
Antihypertensive treatment (%) 71 0 0 56 90 98 N/A <0.001
Cardiovascular disease (%) 21 4 1 14 30 29 0.14 <0.001
Left ventricular hypertrophy (%) 4 7 7 4 4 4 0.91 0.82
Autonomic dysfunction (%) 60 7 7 53 64 83 0.48 <0.001
Retinopathy (%) 81 0 23 83 84 96 <0.001 <0.001
Data represents percentage (%), mean ± SD or median (range). P-values are for unadjusted comparisons (ANOVA) between groups.



























































Figure 1 Flow chart of the cohort.
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system consisting of a radial arterial tonometer embedded
in an articulating strap of a wrist-watch device (BPro™,
HealthStats Singapore). The device was calibrated to
brachial BP and variations in pulse waveform height
over the subsequent measurement period used to calcu-
late brachial AMBP [18]. Calibrated radial waveforms
were then processed at the end of each measurement
session by applying an N-point-moving average to de-
rive CASP [19]. The device reported CASP, CPP, SBP,
diastolic BP (DBP), MAP and heart rate (HR) every
15 minutes during 24 h. Previous validation studies
have shown the BPro device to obtain BP measure-
ments independently of arm positioning, with values
comparable to those obtained with cuff-based devices
[20,21]. Furthermore, we have shown that CASP mea-
surements obtained by the BPro are comparable to
those obtained by accepted gold standard devices for
non-invasive measurements of CASP [22]. AMBP data
was considered adequate if ≥ 14 and ≥ 7 recordings
were obtained during day- and nighttime [23].
Following 15 minutes supine rest, office measurements
of central BP were obtained with the SphygmoCor de-
vice (Atcor Medical, Sydney, Australia) by trained la-
boratory technicians according to guidelines.
Electrocardiographs (ECG) were recorded with Cardiosoft
V6.51 (GE Healthcare, USA) and LVH defined according
to Sokolow-Lyon, Cornell and/or Romhilt-Estes score [24]
by the investigating M.D. Heart rate variability (HRV) wasmeasured after 15 minutes supine rest, during paced deep
breathing [25] to classify autonomic dysfunction. HRV
was assessed by expiration/inspiration variation in heart
rate. While resting in supine position, the patient was
asked to breathe deeply at the rate of 6 breaths per minute
for 1 minute, during which an electrocardiogram was
recorded. Subsequently the means of the difference in
highest and lowest heart rates (HR) during each breathing
cycle were calculated. An abnormal value was < 11 beats
per minute. Retinopathy status obtained from medical re-
cords, and assessed from retinal photographs, taken every
3–24 months, were classified as normal if no retinopathy
was present, and abnormal if presence of simple or prolif-
erative retinopathy or blindness.
All participants had blood samples and phenotypic
characteristics collected. HbA1c was measured by high-
performance liquid chromatography (Variant; Biorad
Laboratories, Germany), urinary albumin excretion rate
(UAER) was measured in 24 h sterile urine collections
by enzyme immunoassay, and plasma creatinine concen-
tration by an enzymatic method (Hitachi 912, Roche
Diagnostics, Germany).
Patients were stratified as normoalbuminuric if two
out of three consecutive measurements contained nor-
moalbuminuria with UAER < 30 mg/24 h, and micro- or
macroalbuminuric if UAER was or previously recorded
between 30–299 mg/24 h or above 300 mg/24 h, in two
out of three consecutive measurements, respectively.
Estimated GFR (eGFR) was calculated by the four
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formula. Based on standardized questionnaires, current
daily use of ≥ 1 cigarettes/cigars/pipes classified smokers.
Previous of CVD was myocardial infarction, stroke, or per-
ipheral arterial disease based on standardized WHO ques-
tionnaires and patient records from Steno Diabetes Center.
Statistical analysis
Normally distributed variables are given as mean ± SD.
The non-normally distributed variable (UAER) is given
as median (range) and log10 transformed before analysis.
Comparisons between groups were performed by un-
paired Student’s t-test or analysis of variance (ANOVA).
Univariate and mulitivariate linear regression compared
hemodynamic variables with covariates. Analysis of covari-
ance (ANCOVA) was applied for multivariable adjustment
when comparing hemodynamic variables in different
groups and in patients with or without complications. Ad-
justments were made for gender, age, 24 h-MAP, 24 h-HR,
eGFR, HbA1c, smoking and antihypertensive treatment. In
comparisons including controls HbA1c and antihyperten-
sive treatment was left out.
The multivariate logistic regression between hemodynamic
variables and diabetic complications also included UAER
and office CASP, CPP or SBP. Although for LVH the ana-
lyses were only adjusted for gender, age and 24 h-MAP.
A two-tailed p-value of < 0.05 was considered statisti-
cally significant. Statistical analyses were performed using
SPSS for Windows, version 20.0 (SPSS, Chicago, IL).
Results
Baseline
Characteristics of the analysed cohort consisting of 629
patients and 86 controls are shown in Tables 1 and 2.
Patients included and excluded from the analyses had
similar age, diabetes duration, gender distribution, HbA1c,
total cholesterol, eGFR, UAER, pulse wave velocity, HRV,
frequency of previous CVD, retinopathy status and pres-
ence of LVH (p > 0.11). Table 3 represent the estimated
marginal means adjusted for gender, age, 24 h-MAP,
24 h-HR, UAER, eGFR, HbA1c, smoking and antihyper-
tensive treatment.
Correlations between covariates and 24 h-CASP, 24
h-CPP and 24 h-SBP in all participants are shown in
Table 4. In short, all three blood pressures correlated
with age, diabetes duration, 24 h-MAP, 24 h-HR, UAER
and eGFR. Furthermore, 24 h-CPP correlated with total
cholesterol, 24 h-SBP was higher in men, and all three
blood pressures were higher in patients receiving AHT.
None of the three blood pressures correlated with HbA1c
or body mass index.
In adjusted analyses only age, diabetes duration, 24
h-MAP, 24 h-HR and UAER correlated with 24 h-CASP,
24 h-CPP and 24 h-SBP (p ≤ 0.001).Correlations between 24 h-CASP and 24-SBP were high
(r = 0.99, p < 0.001 for 24 h, daytime and nighttime BPs).
For comparison, the correlation between office CASP
measured by SphygmoCor and supine brachial SBP was
also high (r = 0.96, p < 0.001), indicative of an overall close
relation between CASP and brachial SBP. However, des-
pite the close correlation, there was a scatter between cen-
tral and brachial measurements as seen in Figure 2.
Moreover, correlations between 24 h-CPP and 24 h-SBP
was much lower (r = 0.72, p < 0.001 for 24 h, daytime and
nighttime BPs). As was the correlation between 24
h-CASP and office CASP (r = 0.67, p < 0.001).24 h-CASP and 24 h-CPP comparison between groups
C and SN had similar 24 h-CASP and 24 h-CPP (un-
adjusted p = 0.60 and 0.96; adjusted p = 0.39 and 0.59)
(Tables 2 and 3). Including further adjustment for body
mass index and total cholesterol did not alter these results
(p ≥ 0.61). Controls compared to all normoalbuminuric
patients (SN and LN) had lower 24 h-CASP and 24 h-CPP
(38 ± 8 and 114 ± 17 vs. 43 ± 10 and 119 ± 14 mmHg, re-
spectively) (p < 0.001 and 0.004; adjusted p < 0.001 for
both). Additional adjustment for body mass index and
total cholesterol did not alter these results (p = 0.016 and
0.018).
Between the groups with LN, Mi, and Ma, 24 h-CASP
was lowest in Mi albeit not statistically significant (p =
0.19), while 24 h-CPP was almost similar between
groups (p = 0.14) (Table 2). Following adjustment, both
24 h-CASP and 24 h-CPP was associated with increased
albuminuria group (p < 0.001 for both) (Table 3). If in-
vestigating level of albuminuria as a continuous variable
in all patients, both 24 h-CASP and 24 h-CPP were in-
dependently associated with UAER (p ≤ 0.001)24 h-CASP, 24 h-CPP and 24 h-SBP in patients with vs.
without history of CVD
The 24 h-CASP, 24 h-CPP and 24 h-SBP in patients
with (n = 134 (21.3%)) vs. without a history of CVD was
121 ± 14, 49 ± 11 and 127 ± 16 vs. 119 ± 14, 43 ± 10
and 129 ± 16 mmHg (p = 0.43, < 0.001 and = 0.18). Fol-
lowing adjustment, 24 h-CASP, 24 h-CPP and 24-h SBP
was higher in patients with a history of CVD (p < 0.001
for all). Per 1 standard deviation (SD) increase in 24
h-CASP, 24 h-CPP and 24-h SBP the odds ratio (OR)
for previous CVD was 3.2 (1.7-6.1), 1.4 (1.0-2.0) and 2.4
(1.3-4.3) (p < 0.001, = 0.045 and = 0.004) (adjusted for
gender, age, 24 h-MAP, 24 h-HR, UAER, eGFR, HbA1c,
smoking, AHT, and either office CASP, office CPP or of-
fice SBP (Table 5). If total cholesterol and body mass
index was further included in the adjusted model, p-
values for a history of CVD were 0.001 for 24 h-CASP,
0.053 for 24 h-CPP and 0.05 for 24 h-SBP.







normo- vs. micro- vs.
macroalbuminuria
Short duration Long duration Micro Macro
p p
n = 86 n = 69 n = 211 n = 163 n = 186
24 h-CASP (mmHg) 114 ± 17 115 ± 13 121 ± 14 119 ± 16 121 ± 13 0.60 0.19
Daytime CASP (mmHg) 118 ± 18 119 ± 14 124 ± 14 122 ± 16 124 ± 13 0.59 0.26
Nighttime CASP (mmHg) 107 ± 16 108 ± 14 114 ± 13 112 ± 16 116 ± 14 0.68 0.029
Office CASP (mmHg) 117 ± 20 112 ± 14 118 ± 18 120 ± 18 120 ± 20 0.057 0.079
24 h-CPP (mmHg) 38 ± 8 38 ± 7 44 ± 10 46 ± 11 46 ± 11 0.96 0.14
Daytime CPP (mmHg) 39 ± 8 39 ± 8 45 ± 10 46 ± 11 46 ± 11 0.59 0.13
Nighttime CPP (mmHg) 36 ± 8 36 ± 7 42 ± 10 44 ± 11 45 ± 11 0.68 0.059
24 h brachial SBP (mmHg) 122 ± 19 124 ± 15 129 ± 15 127 ± 17 131 ± 15 0.43 0.18
Daytime brachial SBP (mmHg) 127 ± 19 129 ± 15 134 ± 15 132 ± 17 134 ± 15 0.37 0.24
Nighttime brachial SBP (mmHg) 113 ± 19 115 ± 15 121 ± 14 119 ± 17 124 ± 15 0.52 0.043
Mean arterial pressure (mmHg) 91 ± 14 93 ± 11 94 ± 10 91 ± 10 94 ± 11 0.43 0.011
24 h heart rate (beats per minute) 66 ± 7 67 ± 7 70 ± 8 69 ± 9 74 ± 10 0.31 <0.001
Data are mean ± SD.
p-values are for unadjusted comparisons (ANOVA) for comparison of controls to patients with short duration of normoalbuminuria or between patients with longstanding normoalbuminuria, microalbuminuria
and macroalbuminuria.

























Short duration Long duration Micro Macro
p p
n = 86 n = 69 n = 211 n = 163 n = 186
24 h-CASP (mmHg) 117 (116–119) 118 (117–119) 119 (118–120) 121 (120–121) 122 (121–122) 0.39 <0.001
Daytime CASP (mmHg) 122 (120–123) 122 (121–123) 121 (121–122) 123 (123–124) 125 (124–126) 0.60 <0.001
Nighttime CASP (mmHg) 109 (107–111) 110 (109–112) 112 (111–114) 114 (113–115) 116 (115–117) 0.30 <0.001
Office CASP (mmHg) 110 (107–112) 111 (109–113) 119 (117–121) 120 (118–122) 118 (115–120) 0.44 0.41
24 h-CPP (mmHg) 38 (36–40) 39 (37–41) 43 (42–44) 46 (44–47) 47 (46–49) 0.59 <0.001
Daytime CPP (mmHg) 39 (37–41) 40 (38–41) 43 (42–45) 46 (45–48) 48 (46–49) 0.74 <0.001
Nighttime CPP (mmHg) 36 (34–38) 37 (35–39) 41 (40–43) 44 (43–45) 46 (44–47) 0.54 <0.001
24 h brachial SBP (mmHg) 126 (125–128) 126 (125–128) 128 (126–129) 130 (127–131) 131 (130–132) 0.98 <0.001
Daytime brachial SBP (mmHg) 132 (129–134) 132 (130–134) 132 (130–134) 134 (133–135) 135 (134–136) 0.90 0.001
Nighttime brachial SBP (mmHg) 116 (114–118) 117 (115–119) 119 (118–121) 122 (120–123) 123 (122–125) 0.56 0.001
24 h-MAP (mmHg) 92 (89–95) 92 (90–95) 95 (94–97) 92 (90–93) 92 (90–94) 0.80 0.004
24 h heart rate (beats per minute) 65 (63–67) 67 (66–69) 72 (70–73) 70 (68–71) 73 (71–74) 0.08 0.005
Estimated marginal means with 95% confidence intervals. P-values are for adjusted comparisons (ANCOVA) of controls to patients with short duration of normoalbuminuria or for comparison between patients with
longstanding normoalbuminuria, microalbuminuria and macroalbuminuria. Adjustments were made for gender, age, 24 h-MAP (except for 24 h-MAP), 24 h HR, eGFR and smoking. Adjustments also included HbA1c and
antihypertensive treatment when comparing patients with normoalbuminuria and long diabetes duration, microalbuminuria and macroalbuminuria.
















Table 4 Correlations between 24 h-CASP, 24 h brachial SBP or 24 h-CPP and covariates in all participants (n = 715)
24 h brachial SBP 24 h-CASP 24 h-CPP
Office CASP r = 0.64, p < 0.001 r = 0.67, p < 0.001 r = 0.56, p < 0.001
24 h-MAP N/A* r = 0.90, p < 0.001 r = 0.32, p < 0.001
24 h-heart rate r = 0.12, p = 0.002 0.17 r = 0.13, p < 0.001
logUAER r = 0.18, p < 0.001 r = 0.17, p < 0.001 r = 0.18, p < 0.001
Diabetes duration r = 0.13, p = 0.01 r = 0.12, p = 0.001 r = 0.40, p < 0.001
Age r = 0.11, p = 0.03 r = 0.12, p = 0.001 r = 0.40, p < 0.001
eGFR r = 0.12, p = 0.02 r = 0.12, p = 0.02 r = 0.23, p < 0.001
HbA1c 0.71 0.78 0.94
Total cholesterol 0.11 0.10 r = 0.08, p = 0.039
Body mass index 0.30 0.38 0.71
Gender Male > female, p = 0.02 0.21 0.19
Antihypertensive treatment Highest in treated patients, p < 0.001 Highest in treated patients, p < 0.001 Highest in treated patients, p < 0.001
Smoking 0.43 0.65 0.46
r-values are Pearson’s coefficients.
MAP: mean arterial pressure, UAER: urinary albumin excretion rate, eGFR: estimated glomerular filtration rate.
* Since SBP is included in MAP.
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The 24 h-CASP, 24 h-CPP and 24 h-SBP in patients
with (n = 27 (4.3%)) vs. without LVH were 125 ± 11,
48 ± 11 and 132 ± 15 vs. 119 ± 14, 44 ± 10 and 128 ±
16 mmHg (p = 0.001, 0.019 and 0.13). Following adjust-
ment for gender, age and 24 h-MAP the significance at-
tenuated (p = 0.09, 0.10 and 0.06). Per 1 SD increase in
24 h-CASP, 24 h-CPP and 24 h-SBP, the OR for LVH
was 2.5 (1.0-6.5), 1.5 (1.0-2.3) and 2.1 (0.9-5.0) (p =
0.057, 0.061, and 0.079) (Table 5).Figure 2 Scatter plot for 24 h-CASP and 24 h-SBP. R = 0.99, p < 0.001.24 h-CASP, 24 h-CPP and 24 h-SBP in patients with vs.
without retinopathy
In patients with (n = 507 (80.6%)) vs. without retinop-
athy, 24 h-CASP, 24 h-CPP and 24 h-SBP was 121 ± 14,
46 ± 11 and 130 ± 15 vs. 115 ± 14, 39 ± 8 and 124 ±
15 mmHg (p < 0.001 for all). Following adjustment all
three BP’s were higher in patients with retinopathy (p =
0.001 for all). Per 1 SD increase in 24 h-CASP, 24 h-CPP
and 24 h-SBP, the OR for presence of retinopathy was
4.4 (2.0-9.6), 1.8 (1.2-2.7) and 3.7 (1.9-7.5) (p < 0.001 for
all) (Table 5). If including total cholesterol and body
Table 5 Adjusted odds ratios between hemodynamic variables and diabetic complications
Complications Patients with disease/ without disease 24 h-CASP
(1 SD = 14.2 mmHg)
24 h-CPP
(1 SD = 10.7 mmHg)
24 h-SBP
(1 SD = 15.6 mmHg)
Cardiovascular disease* n = 134/495 3.19 (1.68-6.05)‡ 1.43 (1.01-2.02)§ 2.39 (1.32-4.33)§
Left ventricular hypertrophy† n = 27/602 2.51 (0.98-6.45) 1.50 (0.98-2.30) 2.14 (0.92-5.01)
Retinopathy* n = 507/122 4.41 (2.03-9.57)‡ 1.77 (1.17-2.68)§ 3.72 (1.85-7.47)‡
Autonomic dysfunction* n = 350/237 3.25 (1.65-6.41)§ 1.64 (1.12-2.639)§ 2.89 (1.54-5.42)§
Values are odds ratios and 95% confidence intervals. Odds ratios are per 1 standard deviation (SD) increase in blood pressure.
*Adjusted for gender, age, 24 h-MAP, 24 h-HR urinary albumin excretion rate, estimated glomerular filtration rate, HbA1c, smoking and antihypertensive treatment.
24 h-CASP is also adjusted for office CASP, 24 h-CPP for office CPP and 24 h-SBP for office SBP.
†Adjusted for gender, age and 24 h-MAP due to low frequency.
‡ p < 0.001, §p < 0.05
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athy were < 0.001 for 24 h-CASP, 0.004 for 24 h-CPP
and < 0.001 for 24 h-SBP.
24 h-CASP, 24 h-CPP and 24 h-SBP in patients with vs.
without autonomic dysfunction
Autonomic dysfunction was present in 350 (59.4%) of 587
assessed patients. Patients with vs. without autonomic
dysfunction had 24 h-CASP, 24 h-CPP and 24 h-SBP of
121 ± 14, 47 ± 11 and 130 ± 16 vs. 117 ± 12, 40 ± 8 and
126 ± 13 mmHg (p < 0.001 for all). Following adjustment,
24 h-CASP, 24 h-CPP and 24 h-SBP remained significantly
higher in patients with autonomic dysfunction (p = 0.001
for all). Per 1 SD increase in 24 h-CASP, 24 h-CPP and
24 h-SBP the OR for presence of autonomic dysfunction
was 3.3 (1.7-6.4), 1.6 (1.1-2.4) and 2.9 (1.5-5.4) (p = 0.001
for all) (Table 5). If we further included total cholesterol
and body mass index in the adjusted model, p-values for
CVD were 0.001, 0.006 and 0.002 for 24 h-CASP, 24
h-CPP and 24 h-SBP, respectively.
Discussion
This is the first study to measure 24 h-CASP and 24
h-CPP in patients with type 1 diabetes. The adjusted values
of 24 h-CASP and 24 h-CPP was lower in controls com-
pared to normoalbuminuric patients, and associated with
increasing degree of albuminuria. Furthermore, 24 h-CASP
and 24 h-CPP was higher in patients with a history of
CVD, retinopathy and autonomic dysfunction, but similar
in patients with and without LVH on ECG. Importantly,
the positive associations were present despite rigorous ad-
justment for baseline characteristics including brachial
24 h-MAP. If we further included office CASP or office
CPP in the adjustments, both 24 h-CASP and 24 h-CPP
remained significantly (p ≤ 0.045) associated with all comp-
lications except albuminuria (data not shown), suggesting
additional risk information of 24 hour measurements
as compared to office measurement. Furthermore, 24
h-CASP was closer associated to diabetic complications as
compared to 24 h-SBP.
As expected, normoalbuminuric type 1 diabetes patients
had higher 24 h-CASP and 24 h-CPP than controls. Patientswith type 1 diabetes are known to develop accelerated arter-
ial stiffness [26] caused by multifactorial mechanisms includi-
ng increased production of advance glycation end products
[27] and increased oxidative stress [28]. Furthermore, insulin
resistance impairs the ability of insulin to decrease pressure
augmentation and CASP [29]. However, controls and
normoalbuminuric patients with short diabetes duration
had similar 24 h-CASP and 24 h-CPP, consistent with
the likelihood that arterial damage caused by diabetes is
a later complication, not appearing until > 10 years of
diabetes duration.
Increasing degree of albuminuria was independently
associated with higher 24 h-CASP and 24 h-CPP. We
expected this, as albuminuria has been shown to be associ-
ated with arterial stiffness [30]. However, our study is the
first to measure 24 h-CASP and 24 h-CPP in patients with
type 1 diabetes and to demonstrate a relationship between
albuminuria and both 24 h-CASP and 24 h-CPP, independ-
ent of MAP, kidney function and conventional risk factors.
Presence of CVD was independently associated with
higher 24 h-CASP and 24 h-CPP. CASP reflects the afterload
on the heart, and as such, it may be a superior indicator of
cardiovascular health, as indicated by a closer association
with the risk of CVD and to constitute a better treatment
target than brachial BP. Increasing CPP results from a com-
bination of higher CASP and lower diastolic central BP. As
cardiac perfusion occurs in diastole it is conceivable, that a
higher CPP will compromise perfusion, which could indicate
that CPP may also be a strong CVD risk marker.
An association between retinopathy and central BP
has never before been investigated, although others have
shown elevated brachial BP (> 130/90 mmHg) in type 2
diabetes to influence development of retinopathy [31]
and high brachial BP (> 150/90 mmHg) in type 1 dia-
betes to enhance progression of retinopathy [32]. We
now show an independent association with central BP
and retinopathy in type 1 diabetes patients.
Longer diabetes duration with presence of autonomic
dysfunction does affect BP regulation. This is partly due to
autonomic dysfunction being associated with altered vascular
adrenoceptor sensitivity and catecholamine release
[33,34], altered renin release [35] and the concurrent
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complications [25]. Thus, by demonstrating an association
between autonomic dysfunction and 24 h central BP our
data concurs with and extends previous findings.
The close correlation between 24 h-CASP and 24 h-SBP
is understandable, as both were calculated from the same
radial pulse wave. Given this close correlation, 24 h-CASP
may not be superior to 24 h-SBP. However, we show that
measurements of 24 h-CASP are feasible, and that values
are strongly associated with diabetic complications, inde-
pendently of brachial 24 h-MAP. Furthermore, we also
exposed 24 h-CPP to be associated with diabetic complica-
tions, and the correlation between 24 h-CPP and 24 h-SBP
was much weaker. Thus, despite the correlations between
central and brachial BPs, the former may offer additional
risk predictive value. This is in accordance with other
studies, which have documented central BP to be closer as-
sociated with end organ damage [37] and superior to bra-
chial BP in predicting outcome [8,9], although, this was not
confirmed in a recent meta-analysis [8]. Furthermore,
central BP is associated with left ventricular mass in type 2
diabetes [38] and with left ventricular function in patients
with abnormal diastolic function [39], commonly present
in diabetes [40]. This is in accordance with our finding of
higher 24 h-CASP in patients with LVH, although the sig-
nificance attenuated on adjustment, which may however
be due to lack of power.
In a future perspective, the 24 h-CASP and 24 h-CPP
may offer additional predictive value to 24 h-SBP in pa-
tients with type 1 diabetes. However, whether these
methods of evaluating central stiffness will add prognostic
information or, if there is any prognosis superiority be-
tween them, can only be determined in prospective stud-
ies. If subtle differences in 24 h-CASP and 24 h-SBP
impact on outcome, targeting control of CASP rather
than SBP may be more efficient in prevention of com-
plications. The CAFE study, a sub-study of the ASCOT
trial, investigated the effect of reducing CASP, and
showed calcium blockers and beta blockers to exhibit
different effect on CASP despite similar effect on SBP
[13]. Another study showed reductions in B-type natri-
uretic peptide (a peptide secreted by the ventricles in
response to strain and a marker of heart failure) in
patients treated with nicorandil, likely secondary to re-
duced CASP [41], suggesting risk reduction associated
with decreased CASP. Finally, a recent study demon-
strated a reduction in left ventricular mass following
treatment with perindopril and indapamide [42], which
could be attributable to reduced CASP [39].
We suggest that CASP and CPP may supplement the
predictive value of brachial BP in patients with type 1
diabetes. Moreover, central BP could be a future target
for BP monitoring and control. Although, follow-up of
this and other future prospective studies are required toverify if modifying CASP and/or CPP may supplement
or even exceed the predictive value of modifying brachial
BP on diabetic complications.
Strengths and limitations
The 24 h-CASP and 24 h-CPP was measured by a wrist
bound tonometric device. This device has previously been
validated with other non-invasive and invasive measure-
ments [19,21,22]. More recently, Komori et al. showed
that arm positioning did not affect BP measurements
by the BPro device [20]. Adjustment were made for
24 h-MAP rather than 24 h-SBP, -DBP or pulse pressure
(PP) -PP, as MAP represents steady components of the BP,
while SBP and PP contain pulsatile components and rep-
resent surrogates for arterial stiffness. Furthermore, 24
h-SBP, 24 h-CASP and 24 h-CPP were derived from the
same pulse wave. Participants in the control group were
compared to patients with short diabetes duration and
normoalbuminuria. They were not fully matched on sev-
eral covariates, including age. This could account for the
lack of differences in the blood pressures between these
two groups. We did however perform aggressive adjust-
ments to compensate for this. The groups of patients with
vs. without LVH were different in size, which limits the
statistical power of these analyses. Furthermore, the diag-
nosis of LVH was solely based on ECG’s, which has a
lower specificity and sensitivity than cardiac imaging.
We did adjust for antihypertensive treatment in
general. However, it was not possible to compare pa-
tients receiving different single agent regiments, as most
patients received several different agents.
Major strengths are the remarkably high sample size,
and the study being from a single center, why the cohort
was likely rather homogenous and receiving similar treat-
ment. The majority of patients had been followed at the
Steno Diabetes Center for more than a decade, rendering
the information on diabetic complications very reliable.
Conclusions
This is the first study to measure 24 h-CASP and 24 h-CPP
in patients with type 1 diabetes. The 24 h-CASP and 24
h-CPP was increased in patients with type 1 diabetes com-
pared to controls and increased with albuminuria, CVD,
retinopathy and autonomic dysfunction independently of
covariates. Furthermore, 24 h-CASP appeared to be
stronger associated with complications as compared to
24 h-SBP. As measurement of 24 h ambulatory central BP
is now feasible, further studies are required to determine its
prognostic significance in patients with diabetes.
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